Literature DB >> 21427570

Review and update of central serous chorioretinopathy.

Alexander Ross1, Adam H Ross, Quresh Mohamed.   

Abstract

PURPOSE OF REVIEW: Greater understanding of central serous chorioretinopathy (CSCR) has changed initial beliefs that CSCR is a benign condition affecting young men with almost complete resolution. CSCR has a spectrum of presentations with more diffuse retinal dysfunction and variations between races. CSCR can affect older individuals and in a subset of patients may lead to significant ocular morbidity. RECENT
FINDINGS: Advances in imaging, particularly in indocyanine green angiography and optical coherence tomography, have led to a greater understanding of the pathophysiology of this condition. Treatments for CSCR are still evolving, in particular photodynamic dynamic therapy using lower doses and reduced fluence showing promising results. More research is required on ideal dosage. Anti-vascular endothelial growth factor treatment offers a new medical treatment modality with promising results.
SUMMARY: There have been recent imaging developments in addition to therapeutic advances for refractory CSCR.

Entities:  

Mesh:

Year:  2011        PMID: 21427570     DOI: 10.1097/ICU.0b013e3283459826

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  51 in total

1.  Repeatability and reproducibility of manual choroidal volume measurements using enhanced depth imaging optical coherence tomography.

Authors:  Jay Chhablani; Giulio Barteselli; Haiyan Wang; Sharif El-Emam; Igor Kozak; Aubrey L Doede; Dirk-Uwe Bartsch; Lingyun Cheng; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-24       Impact factor: 4.799

Review 2.  Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review.

Authors:  Y-R Chung; E J Seo; H M Lew; K H Lee
Journal:  Eye (Lond)       Date:  2013-11-08       Impact factor: 3.775

Review 3.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

Review 4.  Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis.

Authors:  H Q Lu; E Q Wang; T Zhang; Y X Chen
Journal:  Eye (Lond)       Date:  2015-10-30       Impact factor: 3.775

5.  Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy.

Authors:  Mehmet Yasin Teke; Ufuk Elgin; Pinar Nalcacioglu-Yuksekkaya; Emine Sen; Pinar Ozdal; Faruk Ozturk
Journal:  Int J Ophthalmol       Date:  2014-04-18       Impact factor: 1.779

6.  Choroidal imaging: A review.

Authors:  Jay Chhablani; Ian Y Wong; Igor Kozak
Journal:  Saudi J Ophthalmol       Date:  2014-03-20

7.  Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy.

Authors:  Mehmed Uğur Işık; Mehmet Fatih Kağan Değirmenci; Ayhan Sağlık
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

8.  En face enhanced-depth swept-source optical coherence tomography features of chronic central serous chorioretinopathy.

Authors:  Daniela Ferrara; Kathrin J Mohler; Nadia Waheed; Mehreen Adhi; Jonathan J Liu; Ireneusz Grulkowski; Martin F Kraus; Caroline Baumal; Joachim Hornegger; James G Fujimoto; Jay S Duker
Journal:  Ophthalmology       Date:  2013-11-26       Impact factor: 12.079

Review 9.  Photodynamic therapy: current role in the treatment of chorioretinal conditions.

Authors:  D K Newman
Journal:  Eye (Lond)       Date:  2016-01-08       Impact factor: 3.775

10.  Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy.

Authors:  N H Kang; Y T Kim
Journal:  Eye (Lond)       Date:  2013-01-04       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.